Good things are happening these days for New York-based Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP). Thursday, the company revealed that the China National Intellectual Property Administration issued Chinese Patent No. ZL 201480024011.1, a development dating back to April.
This patent, "Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride," is directed to a unique eutectic that characterizes TNX-102 SL, and claims pharmaceutical compositions containing that eutectic and methods of making those compositions.
TNX-102 SL is being developed as a treatment for three indications: post-traumatic stress disorder, fibromyalgia and agitation in Alzheimer’s disease. Marketed oral cyclobenzaprine products are indicated for the relief of muscle spasm.
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat psychiatric, pain and addiction conditions, and biological products to improve biodefense through potential medical counter-measures.
Shares gained six cents, or 3.8%, late Thursday morning, to $1.64, on volume of 175,000 shares
